-
-
-
-
-
-
-
Acer Therapeutics (ACER) and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
-
-
-
-
-
-
-
Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI Conferences
-
-
-
-
-
-
-
Relief Therapeutics (RLFTF) RLF-100 (aviptadil) Receives FDA Orphan Drug Designation
-
-
-
-
-
-
-
NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19
-
-
-
-
-
-
-
Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide Development and Commercialization of ACER-001 for
-
-
-
-
1,162,313 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

